Abstract
The use of peripheral blood as a source of hematopoietic precursors is an alternative to the bone marrow in allogeneic transplantation. Although pediatric allogeneic PBPC experience is limited, there is no reason to believe that the outcome and benefit with PBPC should be different than adults. We describe our initial experience in two children who received PBPC allogeneic transplantation in whom the donors were mobilized with filgrastim. Hematopoietic recovery was achieved on days 14 and 16, and the patients did not develop severe GVHD.
MeSH terms
-
Adolescent
-
Bone Marrow / drug effects
-
Bone Marrow Cells
-
Child
-
Combined Modality Therapy
-
Female
-
Filgrastim
-
Granulocyte Colony-Stimulating Factor / pharmacology
-
Hematopoietic Stem Cell Transplantation*
-
Humans
-
Infant
-
Leukapheresis
-
Leukemia, Myelomonocytic, Chronic / drug therapy
-
Leukemia, Myelomonocytic, Chronic / therapy*
-
Male
-
Mercaptopurine / therapeutic use
-
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / therapy*
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy*
-
Recombinant Proteins
-
Remission Induction
-
Salvage Therapy
-
Transplantation Conditioning
-
Transplantation, Homologous
Substances
-
Recombinant Proteins
-
Granulocyte Colony-Stimulating Factor
-
Mercaptopurine
-
Filgrastim